CYPHERPUNK TECHNOLOGIES INC. (CYPH)
Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
Cypherpunk Technologies Reports Second Quarter 2026 Financial Results
Strategic Education, Inc. and Leading Education Investors Seek Edtech Innovators for Second Signal Labs Cohort
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Sutro Biopharma Reports Second Quarter 2026 Financial Results and Provides Early Update on STRO-004 Phase 1 Study
908 Devices Inc. - 908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates. Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs.
Similarweb Announces Second Quarter 2026 Results
Performance Food Group Company Reports Fourth-Quarter and Full-Year Fiscal 2026 Results
WhiteFiber, Inc. Reports Second Quarter 2026 Results
Recurrent Energy Powers Up Carwarp Energy Park in Australia Under Long-Term Microsoft PPA